Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29367280 | 1.00 | CRBN (0.54) | CRBNDDB1PRMT5WDR77BRD4 | |
| SCHEMBL30830488 | 0.93 | CRBN (0.54) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20046740 | 0.88 | CRBN (0.53) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29641009 | 0.86 | IKZF1 (0.60) | CRBNDDB1PRMT5WDR77IKZF3 | |
| SCHEMBL20046073 | 0.86 | IKZF1 (0.60) | CRBNDDB1PRMT5WDR77IKZF3 | |
| SCHEMBL30047819 | 0.86 | PDK4 (0.50) | CRBNDDB1PDK4IKZF3JAK1 | |
| SCHEMBL27157400 | 0.86 | PDK4 (0.50) | CRBNDDB1PDK4IKZF3JAK1 | |
| SCHEMBL27157397 | 0.86 | CRBN (0.57) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL27376679 | 0.85 | CRBN (0.53) | CRBNDDB1PRMT5WDR77BRD4 | |
| SCHEMBL27223253 | 0.85 | CRBN (0.53) | CRBNDDB1PRMT5WDR77BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448389-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-10-21 | — | — | US | disclosed |
| US-12391686-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-11-07 | — | — | US | disclosed |
| US-20240336643-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| US-20240217970-A1 | PHTHALIMIDO CEREBLON COMPLEX BINDERS AND TRANSCRIPTION FACTOR DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240217970-A1 | PHTHALIMIDO CEREBLON COMPLEX BINDERS AND TRANSCRIPTION FACTOR DEGRADERS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240150348-A1 | BRD9 DEGRADERS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4362939-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2020-06-25 | — | — | US | disclosed |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | CRBN 5/4885DDB1 424/4885PRMT5 1546/4885 |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885DDB1 750/4885PRMT5 1012/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885DDB1 746/4885PRMT5 1002/4885 |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | CRBN 5/4885DDB1 205/4885PRMT5 1375/4885 |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | CRBN 3/4885DDB1 746/4885PRMT5 1002/4885 |
| US-12391686-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | CRBN 56/4885DDB1 699/4885PRMT5 1677/4885 |
| US-20240150348-A1 | BRD9 DEGRADERS AND USES THEREOF | BRD9, BRWD1, BRD2 | CRBN 60/4885DDB1 895/4885PRMT5 3861/4885 |
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | HYPK, PGK1, HIPK1 | CRBN 688/4885DDB1 1230/4885PRMT5 3874/4885 |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | CRBN 5/4885DDB1 424/4885PRMT5 1546/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CRBN 2/4885DDB1 192/4885PRMT5 1288/4885 |
| US-20240336643-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | ALK, JMJD7, ALKBH3 | CRBN 870/4885DDB1 1553/4885PRMT5 3562/4885 |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | CRBN 2/4885DDB1 192/4885PRMT5 1288/4885 |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | ADRM1, BRDT, RBX1 | CRBN 82/4885DDB1 144/4885PRMT5 769/4885 |
| US-20240217970-A1 | PHTHALIMIDO CEREBLON COMPLEX BINDERS AND TRANSCRIPTION FACTOR DEGRADERS AND METHODS OF USE | CRBN, IKZF2, IKZF1 | CRBN 1/4885DDB1 276/4885PRMT5 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.